Monte Rosa reports FY 2022 net loss of $108.5M; MRT-2359 Phase 1/2 data expected H2 2023

Monte Rosa Therapeutics, Inc.

FY 2022 net loss $108.5M (vs $74.0M in 2021); cash & securities $268.1M, runway into 2025.
MRT-2359 Phase 1/2 ongoing; initial Phase 1 PK/PD/safety data expected H2 2023.
FDA granted Fast Track for MRT-2359 in pretreated metastatic NSCLC with L-MYC/N-MYC expression.
VAV1 degrader advanced to lead optimization; multiple development candidates expected in 2023.
Promoted Jennifer Champoux to Chief People & Operations Officer; appointed Magnus Walter SVP Chemical Sciences.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monte Rosa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 16, 2023, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.